ADOPT Phase 4 Interim Analysis: Avatrombopag in Chronic ITP
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, posted on LinkedIn:
”ADOPT Phase 4 interim analysis: Avatrombopag in chronic ITP
Pleased to share this ASH poster as one of the co-authors. The interim dataset provides useful real-world evidence on avarombopag efficacy and safety in clinical practice.
Study overview:
– 199 patients | Mean 9.7 years from ITP diagnosis to enrollment
– 52.3 weeks median avarombopag dosing duration
– 44.1 cumulative weeks with platelet counts ≥30×10⁹/L
– 59.3% had received prior TPO-RA therapy—reflecting a population with established disease
Health-related quality of life outcomes:
→ EQ-5D-5L: improvements in mobility, usual activities, and pain/discomfort from enrollment to month 12
→ FACIT-Fatigue scores: consistent improvement across follow-up
→ WPAI: measurable reductions in work absenteeism, presenteeism, and overall impairment
→ ITP-PAQ: higher scores at month 12 across multiple scales
Safety findings:
18.1% adverse event rate | 12.6% serious AEs | 5.5% treatment-related AEs | 2.0% discontinued due to AEs
The data demonstrates sustained platelet control alongside functional improvements in work and daily activities. This aligns with our broader understanding of how effective haemostatic management translates to patient-reported outcomes.
The full analysis continues. Worth reviewing if you’re managing patients on TPO-RA therapy or evaluating treatment efficacy beyond platelet counts alone. ”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers